Viral Hepatitis
Copyright ©The Author(s) 2003. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 15, 2003; 9(12): 2698-2700
Published online Dec 15, 2003. doi: 10.3748/wjg.v9.i12.2698
N-acetyl cysteine therapy in acute viral hepatitis
Huseyin Gunduz, Oguz Karabay, Ali Tamer, Resat Özaras, Ali Mert, Ömer Fehmi Tabak
Huseyin Gunduz, Department of Internal Medicine and Gastroenterology, Izzet Baysal Medical Faculty, Izzet Baysal University/Bolu, Turkey
Oguz Karabay, Department of Infectious Diseases and Clinical Microbiology, Izzet Baysal Medical Faculty, Izzet Baysal University/ Bolu, Turkey
Ali Tamer, Department of Internal Medicine, Izzet Baysal Medical Faculty, Izzet Baysal University/Bolu, Turkey
Resat Özaras, Ali Mert, Ömer Fehmi Tabak, Department of Infectious Diseases and Clinical Microbiology, Cerrahpasa Medical Faculty, Istanbul University, Findikzade/Ýstanbul, Turkey
Author contributions: All authors contributed equally to the work.
Correspondence to: Huseyin Gunduz, (MD, asistant professor) Department of Internal Medicine and Gastroenterology, Izzet Baysal Medical Faculty, Izzet Baysal University/Bolu, 14100 Turkey. drhuseyingunduz@yahoo.com
Telephone: +903742534656 Fax: +903742534559
Received: July 17, 2003
Revised: July 29, 2003
Accepted: September 2, 2003
Published online: December 15, 2003
Abstract

AIM: To investigate the effect of N-acetyl cysteine (NAC) on acute viral hepatitis (AVH).

METHODS: We administered 200 mg oral NAC three times daily (600 mg/day) to the study group and placebo capsules to the control group. All patients were hospitalized and diagnosed as AVH. Blood total and direct bilirubin, ALT, AST, alkaline phosphatese, albumin and globulin levels of each patient were measured twice weekly until total bilirubin level dropped under 2 mg/dl, ALT level under 100 U/L, follow up was continued and then the patients were discharged.

RESULTS: A total of 41(13 female and 28 male) AVH patients were included in our study. The period for normalization of ALT and total bilirubin in the study group was 19.7 ± 6.9 days and 13.7 ± 8.5 days respectively. In the control group it was 20.4 ± 6.5 days and 16.9 ± 7.8 days respectively (P > 0.05).

CONCLUSION: NAC administration effected neither the time necessary for normalization of ALT and total bilirubin values nor duration of hospitalization, so we could not suggest NAC for the treatment of icteric AVH cases. However, our results have shown that this drug is not harmful to patients with AVH.

Keywords: $[Keywords]